May 11, 2023 Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy
January 17, 2023 Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
December 19, 2022 Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones
November 14, 2022 Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
October 27, 2022 Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia
October 6, 2022 Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia